Alcon Company Profile
What is the competitive landscape for ALCON
ALCON has fifty-eight approved drugs.
There are forty-six US patents protecting ALCON drugs. There is one tentative approval on ALCON drugs.
Summary for Alcon
| US Patents: | 46 |
| Tradenames: | 49 |
| Ingredients: | 41 |
| NDAs: | 58 |
| Patent Litigation for Alcon: | See patent lawsuits for Alcon |
| PTAB Cases with Alcon as patent owner: | See PTAB cases with Alcon as patent owner |
Drugs and US Patents for Alcon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 11,596,599 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | CYCLOGYL | cyclopentolate hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 084108-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 11,197,853 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs Inc | SIMBRINZA | brimonidine tartrate; brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 204251-001 | Apr 19, 2013 | RX | Yes | Yes | 9,421,265 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 9,931,336 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 10,174,017 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alcon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | 4,923,892 | ⤷ Start Trial |
| Alcon Pharms Ltd | TRAVATAN | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021257-001 | Mar 16, 2001 | 6,235,781 | ⤷ Start Trial |
| Alcon Pharms Ltd | TRAVATAN | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021257-001 | Mar 16, 2001 | 5,889,052 | ⤷ Start Trial |
| Alcon Pharms Ltd | NAVSTEL | calcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate | SOLUTION;IRRIGATION | 022193-001 | Jul 24, 2008 | 5,578,578 | ⤷ Start Trial |
| Alcon | PROFENAL | suprofen | SOLUTION/DROPS;OPHTHALMIC | 019387-001 | Dec 23, 1988 | 4,035,376 | ⤷ Start Trial |
| Alcon Pharms Ltd | TRAVATAN | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021257-001 | Mar 16, 2001 | 5,631,287 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALCON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 0.00% | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Ophthalmic Solution | 0.03% | ➤ Subscribe | 2004-12-23 |
International Patents for Alcon Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2871745 | ⤷ Start Trial |
| Ukraine | 114597 | ⤷ Start Trial |
| Australia | 2009273932 | ⤷ Start Trial |
| China | 111743878 | ⤷ Start Trial |
| Japan | 7368661 | ⤷ Start Trial |
| Australia | 2010242800 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alcon Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3752510 | CA 2025 00041 | Denmark | ⤷ Start Trial | PRODUCT NAME: VANZACAFTOR ELLER ET FARMACEUTISK ACCEPTABLELT SALT DERAF, FORTRINSVIS ET CALCIUM-SALT DERAF; REG. NO/DATE: EU/1/25/1943 20250701 |
| 1280520 | 14/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720 |
| 3461484 | C202130024 | Spain | ⤷ Start Trial | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107 |
| 3053913 | 301038 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
| 2957286 | 6/2019 | Austria | ⤷ Start Trial | PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721 |
| 2957286 | 2018/046 | Ireland | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
